ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – London

ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – London

PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference – London on Tuesday, November 18, at 3:00 p.m. GMT/10:00 a.m. ET.

The live and archived fireside chat will be accessible from the Company’s website at , under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit .

Investor Relations:

Courtney Mogerley, Argot Partners

T: 646-368-8014

E:



EN
11/11/2025

Underlying

ANIPANI Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ANI Pharmaceuticals Inc.

 PRESS RELEASE
Free
ANIP ANI Pharmaceuti...

ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conf...

ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – London PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference – London on Tuesday, November 18, at 3:00 p.m. GMT/10:00 a.m. ET. The live and archived fireside chat will be accessible from the Company’s website at , under the Investors section under Events and Presentations. The replay of the webcast will be acce...

November 11, 2025 1 EN
 PRESS RELEASE
Free
ANIP ANI Pharmaceuti...

ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Result...

ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance Record quarterly net revenues of $227.8 million, an increase of 53.6% year-over-yearPurified Cortrophin® Gel net revenues of $101.9 million, an increase of 93.8% year-over-yearRecord quarterly adjusted non-GAAP EBITDA of $59.6 million, an increase of 69.8% year-over-yearDiluted GAAP income per share of $1.13 and record adjusted non-GAAP diluted earnings per share of $2.04Raised 2025 total net revenue guidance to $854.0 million to $873.0 million, adjusted non-GAAP EBITDA to $221.0 million to $228...

November 7, 2025 1 EN
 PRESS RELEASE
Free
ANIP ANI Pharmaceuti...

ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on...

ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its third quarter 2025 financial results on Friday, November 7, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a conference call to discuss the results as follows: ...

October 24, 2025 1 EN
 PRESS RELEASE
Free
ANIP ANI Pharmaceuti...

ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Pre...

ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting Presentation at AAO 2025 part of ongoing NEW DAY data dissemination at medical meetings PRINCETON, N.J., Oct. 16, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that results from the NEW DAY clinical trial of ILUVIEN® (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for use in appropriate patients with diabetic macular edema (DME) will be presented ...

October 16, 2025 1 EN
Free Trial
ANIP ANI Pharmaceuti...

ANI Pharmaceuticals Inc: 1 director

A director at ANI Pharmaceuticals Inc sold 7,292 shares at 94.940USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

ANIP ANI PHARMACEUTICALS INC.
09/04/25 September 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch